Results 181 to 190 of about 6,560 (205)

Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

International Journal of Antimicrobial Agents, 2023
Fangyuan Tian, Zhaoyan Chen
exaly  

Molnupiravir

2021
openaire   +1 more source

Molnupiravir for Covid-19 in Nonhospitalized Patients

New England Journal of Medicine, 2022
Kristian, Thorlund, Kyle, Sheldrick, Edward, Mills   +2 more
openaire   +5 more sources

LC and LC-HRMS studies on stability behavior of molnupiravir an anti-COVID 19 drug

Journal of Liquid Chromatography and Related Technologies, 2021
Nitish Sharma, Ravi P Shāh
exaly  

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

New England Journal of Medicine, 2022
Alejandro Martín-Quirós, Michelle L Brown, Alison Pedley   +2 more
exaly  

Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier

EBioMedicine, 2023
Wen-Ya Peng, Jeffrey W Dalley, Tung-Hu Tsai   +2 more
exaly  

Concise Synthesis of Molnupiravir

Synfacts, 2021
openaire   +1 more source

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis

Annals of Medicine, 2022
Jiake Tang, Chunyi Wang, Yongran Cheng   +2 more
exaly  

Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

International Journal of Antimicrobial Agents, 2023
Jon Salmanton-Garcia, Francesco Marchesi, Iker Falces-Romero   +2 more
exaly  

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Lancet, The, 2023
Nicholas P B Thomas, Tracie-Ann Madden, Andrew Ustianowski   +2 more
exaly